David W. Osborne, Chief Technical Officer at Arcutis Biotherapeutics, Inc. (ARQT), sold 780 shares at $34.57 ($27K) on 2021-03-01, disclosed to the SEC on 2021-03-03.
Scheduled sale ($27k) by Chief Technical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ARQT | SELL | 2022-07-12 | $112K | — | Filing → |
| ARQT | SELL | 2022-04-21 | $45K | — | Filing → |
| ARQT | SELL | 2022-03-07 | $14K | — | Filing → |